Related Articles
Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan
Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition
Early tumor shrinkage as a predictive factor of metastatic renal cell carcinoma in molecular targeted therapy: A single institutional study
Lysosome‑associated membrane protein 2 (LAMP‑2) expression induced by miR‑194‑5p downregulation contributes to sunitinib resistance in human renal cell carcinoma cells
Synergistic interaction between sorafenib and gemcitabine in EGFR‑TKI‑sensitive and EGFR‑TKI‑resistant human lung cancer cell lines